NeoGenomics, Inc. (NASDAQ: NEO) saw some unusual option deals on Thursday. Stock traders bought 3,480 call options on the company. This is an increase of 1.008% over the typical daily volume of 314 call options.
A number of research analysts recently released reports on the stock. Zacks Investment Research sold NeoGenomics on Tuesday the 17th. Morgan Stanley lowered its price target on NeoGenomics shares from $ 64.00 to $ 58.00 and rated the company in a research release on Monday 9. Needham & Company LLC confirmed a “Buy” rating in a research release on Monday, August 9th, with a target price of $ 55.00 on NeoGenomics stock. Benchmark raised its target price on NeoGenomics stock from $ 46.00 to $ 50.00 and announced it to the company on Thursday June 26. Finally, Goldman Sachs Group began a research note on Thursday June 3rd Reporting on NeoGenomics’ stocks. They posted a “Buy” rating and a target price of $ 55.00 for the company. Two analysts have given the stock a hold rating and eight with a buy rating. Based on data from MarketBeat, NeoGenomics currently has a consensus rating of “Buy” and a consensus price target of $ 52.28.
Several institutional investors recently changed their holdings in the company. Vanguard Group Inc. increased its position in NeoGenomics stocks by 1.4% in the second quarter. Vanguard Group Inc. now owns 12,197,560 shares in the medical research company, valued at $ 550,964,000, after purchasing an additional 168,921 shares last quarter. Artisan Partners Limited Partnership increased its position in NeoGenomics stocks by 2.6% in the first quarter. Artisan Partners Limited Partnership now owns 4,852,328 shares in the medical research company, valued at $ 234,028,000, after acquiring an additional 124,841 shares last quarter. Janus Henderson Group PLC increased its position in NeoGenomics stocks by 51.0% in the first quarter. Janus Henderson Group PLC now owns 4,103,784 shares in the medical research company valued at $ 197,926,000 after acquiring an additional 1,386,761 shares last quarter. State Street Corp increased its position in NeoGenomics stocks by 5.8% in the 2nd quarter. State Street Corp now owns 3,489,471 shares in the medical research company, valued at $ 157,619,000, after acquiring an additional 190,095 shares last quarter. Finally, Brown Advisory Inc. increased its stake in NeoGenomics shares by 2.2% in the first quarter. Brown Advisory Inc. now owns 3,142,710 shares in the medical research company valued at $ 151,573,000 after purchasing an additional 67,143 shares during the reporting period. Institutional investors own 90.05% of the company’s shares.
These startup veterans and tech experts are turning the beverage distribution model on its head
NEO stock fell $ 0.18 during Thursday’s trading to hit $ 49.94. The company had a trading volume of 1,538,575 shares versus an average volume of 831,009. The company has a quick ratio of 7.07, a current ratio of 7.28, and debt of 0.46. The company has a 50-day moving average price of $ 46.65 and a 200-day moving average price of $ 45.55. NeoGenomics has a 12-month low of $ 34.18 and a 12-month high of $ 61.57. The stock has a market capitalization of $ 6.14 billion, a price / earnings ratio of 87.62, and a beta of 0.66.
NeoGenomics company profile
NeoGenomics, Inc. is a clinical laboratory company providing cancer genetics diagnostic testing and pharmaceutical services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment provides cancer testing services to community pathologists, hospitals, academic centers, and oncology groups.
Further Reading: Investing in Blue Chip Stocks
This instant news alert was generated through narrative science technology and financial data from MarketBeat to provide readers with the fastest, most accurate coverage. This story has been reviewed by the editorial staff of MarketBeat prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $ 1,000 in NeoGenomics now?
Before you even think about NeoGenomics, this is what you should hear.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly whispering to their customers to buy now, before the broader market takes hold … and NeoGenomics wasn’t on the list.
While NeoGenomics is currently rated “Buy” by analysts, top-rated analysts think these five stocks are better buys.
Check out the 5 stocks here